NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
Clinical Trials
5 trialsNCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT03008148 2021-05-11
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Johnpro Biotech, Inc.
Phase 2/3 Unknown
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated